TWIST1-Induced miR-424 Reversibly Drives Mesenchymal Programming while Inhibiting Tumor Initiation.

Autor:	Drasin DJ; Program in Molecular Biology, University of Colorado Anschutz Medical Campus, Aurora, Colorado., Guarnieri AL; Department of Pharmacology, University of Colorado Anschutz Medical Campus, Aurora, Colorado., Neelakantan D; Program in Molecular Biology, University of Colorado Anschutz Medical Campus, Aurora, Colorado., Kim J; Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado., Cabrera JH; Department of Pharmacology, University of Colorado Anschutz Medical Campus, Aurora, Colorado., Wang CA; Department of Pharmacology, University of Colorado Anschutz Medical Campus, Aurora, Colorado., Zaberezhnyy V; Department of Biochemistry and Molecular Genetics, University of Colorado Anschutz Medical Campus, Aurora, Colorado., Gasparini P; Department of Molecular Virology, Immunology and Molecular Genetics, Ohio State University, Columbus, Ohio., Cascione L; Department of Molecular Virology, Immunology and Molecular Genetics, Ohio State University, Columbus, Ohio., Huebner K; Department of Molecular Virology, Immunology and Molecular Genetics, Ohio State University, Columbus, Ohio., Tan AC; Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado., Ford HL; Program in Molecular Biology, University of Colorado Anschutz Medical Campus, Aurora, Colorado. Department of Pharmacology, University of Colorado Anschutz Medical Campus, Aurora, Colorado. Department of Biochemistry and Molecular Genetics, University of Colorado Anschutz Medical Campus, Aurora, Colorado. Heide.Ford@ucdenver.edu.
Jazyk:	angličtina
Zdroj:	Cancer research [Cancer Res] 2015 May 01; Vol. 75 (9), pp. 1908-21. Date of Electronic Publication: 2015 Feb 25.
DOI:	10.1158/0008-5472.CAN-14-2394
Abstrakt:	Epithelial-to-mesenchymal transition (EMT) is a dynamic process that relies on cellular plasticity. Recently, the process of an oncogenic EMT, followed by a reverse mesenchymal-to-epithelial transition (MET), has been implicated as critical in the metastatic colonization of carcinomas. Unlike governance of epithelial programming, regulation of mesenchymal programming is not well understood in EMT. Here, we describe and characterize the first microRNA that enhances exclusively mesenchymal programming. We demonstrate that miR-424 is upregulated early during a TWIST1 or SNAI1-induced EMT, and that it causes cells to express mesenchymal genes without affecting epithelial genes, resulting in a mixed/intermediate EMT. Furthermore, miR-424 increases motility, decreases adhesion, and induces a growth arrest, changes associated with a complete EMT that can be reversed when miR-424 expression is lowered, concomitant with an MET-like process. Breast cancer patient miR-424 levels positively associate with TWIST1/2 and EMT-like gene signatures, and miR-424 is increased in primary tumors versus matched normal breast. However, miR-424 is downregulated in patient metastases versus matched primary tumors. Correspondingly, miR-424 decreases tumor initiation and is posttranscriptionally downregulated in macrometastases in mice, suggesting the need for biphasic expression of miR-424 to transit the EMT-MET axis. Next-generation RNA sequencing revealed miR-424 regulates numerous EMT and cancer stemness-associated genes, including TGFBR3, whose downregulation promotes mesenchymal phenotypes, but not tumor-initiating phenotypes. Instead, we demonstrate that increased MAPK-ERK signaling is critical for miR-424-mediated decreases in tumor-initiating phenotypes. These findings suggest miR-424 plays distinct roles in tumor progression, potentially facilitating earlier, but repressing later, stages of metastasis by regulating an EMT-MET axis. (©2015 American Association for Cancer Research.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu